Blood cancers

Venetoclax ‘vaulting over the wall’ of R-CHOP results in DLBCL

Addition of venetoclax to R-CHOP has the potential to improve outcomes for patients with the worst prognosis for diffuse large B-cell lymphoma (DLBCL), those with overexpressed Bcl-2. In the phase 2 CAVALLI study involving 206 patients with advanced stage DLBCL, the addition of venetoclax to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) resulted in ...

Already a member?

Login to keep reading.

© 2021 the limbic